Effects of Aldosterone on Human Atherosclerosis: Plasma Aldosterone and Progression of Carotid Plaque

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 706-711

  de Rita, Omar ^a   Hackam, Daniel G ^b   Spence, J David ^b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CHOLESTEROL;

ADULT; AGE; ALDOSTERONE BLOOD LEVEL; ARTICLE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84869089106     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.04.014     Document Type: Article

References (48)

1. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
2. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400-2406.
3. Gros R., Ding Q., Armstrong S., et al. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 2007, 292:C788-C794.
4. Feldman R.D., Gros R. Rapid vascular effects of steroids - a question of balance?. Can J Cardiol 2010, 26(suppl A):22A-26A.
5. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
6. Brown N.J. Aldosterone and vascular inflammation. Hypertension 2008, 51:161-167.
7. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
8. Neves M.F., Amiri F., Virdis A., Diep Q.N., Schiffrin E.L. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005, 83:999-1006.
9. Montezano A.C., Callera G.E., Yogi A., et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28:1511-1518.
10. Leibovitz E., Ebrahimian T., Paradis P., Schiffrin E.L. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009, 27:2192-2200.
11. Keidar S., Hayek T., Kaplan M., et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41:955-963.
12. Strawn W.B. Eplerenone antagonizes atherosclerosis, but what is the agonist?. Hypertension 2005, 46:1093-1094.
13. Takai S., Jin D., Muramatsu M., et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135-1139.
14. Suzuki J., Iwai M., Mogi M., et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006, 26:917-921.
15. Imanishi T., Ikejima H., Tsujioka H., et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008, 51:734-741.
16. Savoia C., Touyz R.M., Amiri F., Schiffrin E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.
17. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009, 94:3623-3630.
18. Spence J.D., Eliasziw M., DiCicco M., Hackam D.G., Galil R., Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 2002, 33:2916-2922.
19. Inaba Y., Chen J.A., Bergmann S.R. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012, 220:128-133.
20. Spence J.D. Carotid plaque measurement is superior to IMT. Invited editorial comment on: carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis-Yoichi Inaba, MD, Jennifer A. Chen, MD, Steven R. Bergmann, MD, PhD. Atherosclerosis 2012, 220:34-35.
21. Klein J.H., Hegele R.A., Hackam D.G., et al. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008, 28:1851-1856.
22. Spence J.D., Barnett P.A., Marian A.J., et al. Plasma homocyst(e)ine, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 1999, 30:969-973.
23. Hegele R.A., Ban M.R., Anderson C.M., Spence J.D. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Invest Med 2000, 48:198-202.
24. Spence J.D., Ban M.R., Hegele R.A. Lipoprotein lipase (LPL) gene variation and progression of carotid artery plaque. Stroke 2003, 34:1178-1182.
25. Hegele R.A., Al-Shali K.Z., House A.A., et al. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke 2005, 36:2566-2570.
26. Lanktree M.B., Hegele R.A., Schork N.J., Spence J.D. Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease. Circ Cardiovasc Genet 2010, 3:215-221.
27. Sharma R., Katz J. Preliminary studies on human aldosterone synthase (CYP11B2) gene polymorphism, matrix metalloprotease-9, apoptosis, and carotid atherosclerosis plaque size by proton magnetic resonance imaging. J Renin Angiotensin Aldosterone Syst 2010, 11:198-204.
28. Holaj R., Zelinka T., Wichterle D., et al. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007, 25:1451-1457.
29. Gonzalez-Perez P., Stiefel P. Increased carotid intima-media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration. J Hypertens 2008, 26:1499-1500.
30. Wang J.G., Staessen J.A., Li Y., et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006, 37:1933-1940.
31. Finn A.V., Kolodgie F.D., Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis. A point of view from pathology. Arterioscler Thromb Vasc Biol 2010, 30:177-181.
32. Spence J.D., Hegele R.A. Noninvasive phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:e188-e189.
33. Spence J.D. The importance of distinguishing between diffuse carotid intima medial thickening and focal plaque. Can J Cardiol 2008, 24:61C-64C.
34. Stumpe K.O., Agabiti-Rosei E., Zielinski T., et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007, 1:97-106.
35. Spence J.D., Hackam D.G. Treating arteries instead of risk factors. A paradigm change in management of atherosclerosis. Stroke 2010, 41:1193-1199.
36. Barnett P.A., Spence J.D., Manuck S.B., Jennings J.R. Psychological stress and the progression of carotid artery disease. J Hypertens 1997, 15:49-55.
37. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
38. Spence J.D., Barnett P.A., Bulman D.E., Hegele R.A. An approach to ascertain probands with a non traditional risk factor for carotid atherosclerosis. Atherosclerosis 1999, 144:429-434.
39. Spence J.D. Technology insight: ultrasound measurement of carotid plaque-patient management, genetic research, and therapy evaluation. Nat Clin Pract Neurol 2006, 2:611-619.
40. McCurley A., Jaffe I.Z. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012, 350:256-265.
41. Young M.J., Rickard A.J. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 2012, 350:248-255.
42. Skott O., Uhrenholt T.R., Schjerning J., et al. Rapid actions of aldosterone in vascular health and disease-friend or foe?. RALES, EPHESUS and redox. Pharmacol Ther 2006, 111:495-507.
43. Funder J.W. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93:121-125.
44. Tirosh A., Garg R., Adler G.K. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010, 12:252-257.
45. Laragh J.H. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med 1976, 61:797-810.
46. Spence J.D. Lessons from Africa: the importance of measuring plasma renin and aldosterone in resistant hypertension. Can J Cardiol 2012, 28:254-257.
47. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
48. Ainsworth C.D., Blake C.C., Tamayo A., Beletsky V., Fenster A., Spence J.D. 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 2005, 36:1904-1909.